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Glioblastoma multiforme (GBM) is the most aggressive type of malignant brain tumour, which is associated
with a poor two-year survival rate and a high rate of fatal recurrence near the original tumour. Focal/local
drug delivery devices hold promise for improving therapeutic outcomes for GBM by increasing drug
concentrations locally at the tumour site, or by facilitating the use of potent anti-cancer drugs that are
poorly permeable across the blood brain barrier (BBB). For inoperable tumours, stereotactic delivery to
the tumour necessitates the development of nanoscale/microscale injectable drug delivery devices.
Herein we assess the ability of a novel class of polymer nanotube (based on poly(ethylene glycol) (PEG))
to load doxorubicin (a mainstay breast cancer therapeutic with poor BBB permeability) and release it
slowly. The drug loading properties of the PEG nanotubes could be tuned by varying the degree of
carboxylic acid functionalisation and hence the capacity of the nanotubes to electrostatically bind and
load doxorubicin. 70% of the drug was released over the first seven days followed by sustained drug
release for the remaining two weeks tested. Unloaded PEG nanotubes showed no toxicity to any of the
cell types analysed, whereas doxorubicin loaded nanotubes decreased GBM cell viability (C6, U-87 and
U-251) in a dose dependent manner in 2D in vitro culture. Finally, doxorubicin loaded PEG nanotubes
significantly reduced the viability of in vitro 3D GBM models whilst unloaded nanotubes showed no
cytotoxicity. Taken together, these findings show that polymer nanotubes could be used to deliver
alternative anti-cancer drugs for local therapeutic strategies against brain cancers.Introduction
Glioblastoma multiforme (GBM) is classied as a grade IV
glioma by the World Health Organisation (WHO)1 and is the
most common and aggressive malignant brain tumour. Current
therapeutic strategies result in a median survival rate that is less
than two years.2 Symptoms of GBM include thromboembolism,
seizures, headaches, vision problems, memory loss and nausea/
vomiting.3 The current treatment of newly diagnosed GBM
patients utilises surgical resection of the tumour to relieve the
symptoms, decrease the bulk of the tumour and to aid the
diagnosis. However, surgery is only applicable to 65–75% of
patients (depending on the position of the tumour).4 Following
surgery, patients typically receive radiotherapy for 6 weeks,ences, Cardiff University, King Edward VII
landb@cardiff.ac.uk
en, Max Bergmann Center of Biomaterials
Germany
of Medicine, University College, Dublin,
sity, Jeddah 21589, Saudi Arabia
(ESI) available: Additional nanotube
. See DOI: 10.1039/d0na00471e
8–4509together with an adjuvant chemotherapeutic treatment of an
alkylating agent, temozolomide (TMZ).2 However, GBM is
associated with a high rate of recurrence due to the inltrative
nature of GBM.5 Despite the recent advances in surgery, radia-
tion and chemotherapy, the prognosis has not signicantly
improved and thus development of new therapies is needed.
The rationale for local delivery of chemotherapeutic agents
to GBM include decreasing the adverse effects of systemically
administered therapeutics, targeting the tumour site, and
expanding the range of chemotherapeutic options.6 Local
delivery can be achieved by direct insertion of a drug or drug
delivery system into the GBM surgical resection cavity or via
injection into inoperable GBM.7,8 Local delivery of chemother-
apeutic agents also holds the potential to increase the concen-
tration of the drug at the tumour site without a corresponding
increase in the systemic concentration and harmful off-target
effects.9 GBM is locally inltrative and recurrence is reported
to oen occur within 2 cm of the original tumour location (80–
90% of the cases).5,10 Local delivery of chemotherapeutic agents
to the site of the resected tumour may therefore have a better
chance of killing peripheral non-resected tumour cells. In
addition, local delivery bypasses the blood brain barrier (BBB)
thus enabling the utilisation of therapeutics that cannot crossThis journal is © The Royal Society of Chemistry 2020
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View Article Onlinethe BBB with sufficient efficiency.11 For example, direct intra-
cranial injection via convection enhanced delivery has allowed
the administration of carboplatin,12 a hydrophilic drug that
does not freely cross the BBB.13 Local drug delivery strategies
therefore vastly expand the range of possible chemotherapeutic
agents available for GBM therapies. For example, a drug such as
doxorubicin (a mainstay therapeutic for many breast cancers)
offers exciting prospects, since it has shown much better cyto-
toxic potency than TMZ against GBM cells in vitro.14
Injectable drug delivery systems, which control the release of
a drug at the tumour site, offer the possibility for a single
intervention in conjunction with radiotherapy and other
chemotherapeutics. Whilst Gliadel® wafers have been
commonly used to release carmustine into the GBM resection
cavity,15 these wafers are 1.45 cm in diameter making them
unsuitable for applications requiring injection (e.g. GBM
without resection). Injectable drug delivery systems may there-
fore hold advantages over wafers, not just in terms of range of
utility, but also in terms of better drug penetration depth and
avoiding implant dislodgements.9,16–18
We hypothesised that by combining the high GBM cyto-
toxicity of doxorubicin with an injectable polymer nanotube
drug delivery system, we could achieve sustained drug release
with high therapeutic potential. It should be noted that the use
of doxorubicin for this nanotube-based drug delivery system
also holds other potential advantages. First, the drug has
a different mechanism of action from TMZ,19 thus potentially
avoiding the chemoresistance pathway of TMZ (which is very
common in GBM20). Second, the drug is reported to have radio-
sensitisation properties,21–23 which may aid concurrent radio-
therapy. Finally, the drug has a favourable chemical dissocia-
tion charge for electrostatic binding to the drug delivery
system.24
Nanotubes are nanoscale hollow tubes with a high aspect
ratio. Carbon nanotubes have been heavily investigated for
applications in the delivery of therapeutics, including delivery
to the central nervous system.25–27 However, certain types of
nanotubes may exhibit asbestos-like toxicity brought about by
their rigidity and high aspect ratio.28 Polymer nanotubes,
synthesized in a sacricial template, offer an exciting alternative
to carbon nanotubes for drug delivery applications.29 A wide
range of chemical compositions can be investigated, each
conferring different physical properties and differing cytotox-
icity proles.24,30,31 Herein, our aim was to investigate the use of
poly(ethylene glycol) (PEG) based nanotubes for doxorubicin
delivery to GBM cells in culture. Furthermore, we aimed to tailor
the drug loading and the release prole via simple modica-
tions to the nanotube synthesis procedure.
Experimental
Materials and methods
Synthesis and characterisation of polymer nanotubes. All
reagents and solvents were purchased from Sigma unless
otherwise stated. A schematic depiction of the nanotube
synthesis process is provided in Fig. 1a. The polymer nano-
tubes were synthesised via a modication of the previouslyThis journal is © The Royal Society of Chemistry 2020developed protocol.24 Briey, a monomer solution was
prepared by dissolving poly(ethylene glycol)diacrylate (Mw ¼
575 g mol1) in acetone (5% wt per vol) together with the
photoinitiator 2-hydroxy-2-methylpropiophenone (HMPP)
(5 : 1 molar ratio of diacrylate to photoinitiator). To uo-
rescently label the nanotubes, 10 mg of maleimide function-
alized Atto dye (either Atto 463, Atto 565 or Atto 467 (ATTO-
TEC GmbH)) was added to 1 mL of the monomer solution.
100 mL of the monomer solution were spread evenly across
both sides of an Anodisc™ anodized aluminium oxide (AAO)
membrane (Whatman® 200 nm pore size and 47 mm disc
diameter, pore depth ¼ 60 mm). The monomer inltrated AAO
membrane was then ushed with nitrogen for two minutes
and crosslinked by exposing it to UV light for two minutes
(Ko¨hler Technik lamp, UV wavelength ¼ 365 nm, intensity ¼
1800 mW cm2).
To yield the free PEG based nanotubes, the AAO membrane
was dissolved in sodium hydroxide solution (6 mL, 1 M) for 10,
40 or 70 minutes using an ultrasonic bath XUBA1 (Grant)
including 30 seconds of probe sonication (Qsonica Sonicator
Q55, Fischer Scientic). The standard dissolution protocol used
was 40 minutes long, but shorter and longer times were tested
to evaluate the effect of dissolution time on drug loading. For all
cell studies, PEG nanotubes produced with 40 minutes disso-
lution time were used. The yellow-white dispersion obtained
was washed twice with 1 M sodium hydroxide (1 mL) by
centrifugation (13 400 rpm, Minispin (Eppendorf)) and
replacement of the supernatant. This was followed by three
washes with water and two washes in methanol before subse-
quent drying under laminar ow.
Scanning electron microscopy (SEM) was carried out using
a Zeiss LEO 1525 equipped with GEMINI eld emission column
with an accelerating voltage of 10 kV. Samples were re-
suspended in methanol and a drop was dried on a round
glass cover slip attached to an aluminium stub via carbon bi-
adhesive tape. Prior to analysis, the samples were sputtered
with chromium at 100 mA (24 seconds) (Quorum Q150T).
Fluorescence microscopy was carried out using a SP5 laser
scanning confocal microscope (Leica). Fluorescently labelled
and/or doxorubicin loaded nanotubes were re-suspended
in phosphate buffered saline (PBS) at a concentration of
10 mg mL1 and images were acquired using 100 objective lens
and 4 digital zoom.
Raman spectroscopy was performed using an Alpha P spec-
trometer (Bruker) equipped with a DGTS detector and ATR
accessory. Pellets of dried nanotubes were investigated in
comparison to a crosslinked PEGDA hydrogel (synthesised as
described previously32) to act as a reference without sodium
hydroxide exposure.Cell culture
Primary human astrocytes, isolated from the cerebral cortex
(ScienCell Research Laboratories) were cultured in astrocyte
medium (ScienCell Cat#1801). The human U-87 glioblastoma
multiforme cell line and the human U-251 glioblastoma astro-
cytoma cell line were kind gis from Professor Johan BengzonNanoscale Adv., 2020, 2, 4498–4509 | 4499
Fig. 1 Poly(ethylene glycol) (PEG) based polymer nanotubes via template mediated synthesis. (a) Schematic depiction of the polymer nanotube
synthesis procedure. Scanning electron microscope images of bundles of PEG nanotubes (b) and the end of an individual nanotube (c). (d)
Fluorescent microscope imaging of Atto 647 labelled nanotubes with corresponding brightfield image and subsequent overlay (scale bar
represents 20 mm).
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View Article Online(Lund University) and were cultured in Dulbecco's Modied
Eagle Medium (DMEM) (ThermoFisher Cat#31966021) supple-
mented with 10% fetal bovine serum (FBS, Hyclone Thermo-
Fisher) and 1% penicillin/streptomycin (PS, Life Technologies).
Rat C6 glial tumour cells were purchased from Sigma Aldrich
(Cat#92090409) and cultured in DMEM/F-12 Ham media
(ThermoFisher Cat#11330032) supplemented with 10% FBS and
1% PS. Cells were cultured at 37 C with 5% CO2 using standard
cell culturing techniques.Cell viability analysis of the nanotubes
Astrocytes were seeded at a density of 10 000 cells per well in
a 96-well plate and le overnight to attach. Polymer nanotubes
and MWCNTs (Sigma Aldrich, D  L 110–170 nm  5–9 mm
Cat#659258), were washed in ethanol and dried under laminar
ow, before resuspension in cell culture medium for a serial4500 | Nanoscale Adv., 2020, 2, 4498–4509dilution from 120 mg mL1 to 7.5 mg mL1. Medium was
removed from the cells and replaced with the appropriate
nanotube suspension. Control wells received medium without
nanotubes. Aer incubation for 24 hour or 72 hours, the plates
were analysed using a PrestoBlue assay (ThermoFisher, 10%
diluted in cell culture medium) according to the manufacturer's
protocol. PrestoBlue solution was added to empty wells to act as
a blank. Fluorescence was measured using a Tecan GENios
plate reader (Tecan), and the cell viability of the test conditions
was calculated by normalising to the metabolic activity of the
untreated control cells (termed 100% viable). Experiments were
carried out in quadruplicate with an average being taken (n¼ 4)
and error bars on the graphs plotted represent the standard
deviation. Representative light microscope images were taken
using an (Olympus IX73) microscope at the end of the test
period.This journal is © The Royal Society of Chemistry 2020
Paper Nanoscale Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
4 
A
ug
us
t 2
02
0.
 D
ow
nl
oa
de
d 
on
 1
0/
29
/2
02
0 
12
:4
6:
45
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineAnalysis of drug loading/release characteristics of the
nanotubes
The drug loading capacity of the three different polymer
nanotubes (10, 40, or 70 minutes dissolution time – termed
PEG-10, PEG-40 or PEG-70, respectively) was evaluated in
comparison to MWCNTs. 120 mg of each type of nanotube, were
suspended in 1 mL of doxorubicin (LC Laboratories) dissolved
in water (containing 0.1% dimethyl sulfoxide (DMSO, Sigma))
at the following concentrations 1.5, 3, 6, 12, 24, 48, and
96 mg mL1, and incubated at room temperature in the absence
of light for 72 hours. Doxorubicin solutions without nanotubes
were incubated as above to control for doxorubicin degrada-
tion.33 Aer incubation, the suspensions were centrifuged for 3
minutes at 13 400 rpm and the concentration in the superna-
tant was determined via UV absorbance at 490 nm (LT-5000 MS
plate reader, LabTech) in comparison to the doxorubicin
references using a standard curve. The percentage of doxoru-
bicin loaded to the nanotubes was calculated by subtracting the
doxorubicin remaining in the supernatant aer loading from
the doxorubicin in the reference samples (total doxorubicin).
This value was then divided by the total doxorubicin and
multiplied by 100. This method therefore measures the doxo-
rubicin depletion in the solution due to uptake by the
nanotubes.
To analyse the drug release prole from the nanotubes, 120
mg of the different nanotube types were loaded with 96 mg of
doxorubicin (in 1 mL water (0.1% DMSO)) at room temperature,
in the absence of light, for 72 hours. This represents a drug to
nanotube weight ratio of 0.8 : 1 and is passed the saturation
point of all nanotube types tested (where no more doxorubicin
can be loaded to the nanotubes). At time zero the nanotubes
were centrifuged at 13 400 rpm and the supernatant was
removed. Drug release was measured from these nanotubes by
re-suspending them in 1 mL of PBS and incubating them at
37 C in the absence of light. Complete removal and replace-
ment of PBS was repeated at subsequent time points, retaining
the collected supernatants at 20 C for concentration analysis
(via UV absorbance as described above) at the end of the 21 day
period. This experiment was performed ve times (n ¼ 5).
Average values were plotted with error bars representing the
standard deviation.Loading the nanotubes for cytotoxicity experiments
For all subsequent studies PEG nanotubes produced with a 40
minute dissolution time (PEG-40) were used. For all cell culture
experiments, a drug to nanotube weight ratio of 0.08 : 1 was
used which was below the saturation point (i.e. all doxorubicin
is loaded to the nanotubes). The reason this ratio was chosen,
instead of the 0.8 : 1 used for saturating the nanotubes, is
because it means that no free doxorubicin is contained within
the medium prior to the cell experiments. Therefore, cytotox-
icity shown must be due to the released drug. In addition, this
loading ratio also allows comparisons to be drawn with previous
experiments.24 Doxorubicin loading was carried out as
described above using 120 mg of nanotubes (PEG-40 or MWCNT)
loaded with 9.6 mg of doxorubicin. Aer 72 hours at roomThis journal is © The Royal Society of Chemistry 2020temperature, the nanotubes were washed twice in the appro-
priate cell culturemedium for the experiment (by centrifugation
and removal/replacement of the supernatant) and resuspended
at the appropriate concentration for a subsequent dilution
series.
Efficacy testing of drug delivery: 2D culture
C6, U-251 and U-87 cell lines were seeded at a density of 10 000
cell per well in a 96-well plate and le overnight to adhere. The
medium was replaced with 100 mL of medium containing
nanotubes at concentrations ranging from 7.5 to 120 mgmL1 of
either unloaded or doxorubicin loaded nanotubes. Cell viability
was analysed, as described above, aer 1 and 3 days of incu-
bation with the nanotubes. Experiments were performed in
quadruplicate.
Injection feasibility and cytotoxicity analysis of unloaded vs.
drug loaded polymer nanotubes in 3D culture
C6 glioma cells were seeded in Matrigel™ (BD Biosciences) at
a concentration of 500 cells per mL of Matrigel. Firstly, 15 mL of
Matrigel devoid of cells was pipetted as a droplet onto the
bottom of wells in a 24-well plate and allowed to polymerise at
37 C for 15 minutes before another 15 mL of Matrigel con-
taining cells (1000 cells per mL) was placed on top of the poly-
merised Matrigel. This two-step process prevents cell migration
out of the droplet on the surface of the tissue culture plastic.
This was le for a further 30 minutes before the addition of
1 mL of medium per well and incubation at 37 C overnight.
PEG nanotubes (either unloaded or doxorubicin loaded as
described above) were resuspended in cell culture medium to
a concentration of 1675 mg mL1 and 4 mL was administered
into the centre of the cell/Matrigel droplet using a 30-gauge
stainless steel cannula connected by ne polyethylene tubing to
a microsyringe (50 mL, Hamilton) (nal concentration of 7.5 mg
mL1). PrestoBlue analysis was carried out as above but using
a longer incubation time of 3 hours to allow diffusion of Pres-
toBlue through the Matrigel to the cells. Light microscope
imaging of the droplet was performed post injection (to conrm
correct positioning) and at the nal time point. Confocal
microscope live/dead imaging was performed 3 days post-
injection using calcein AM solution (PromoKine) and propi-
dium iodide (Sigma) as previously described.34,35 Experiments
were performed in quadruplicate.
Analysis of polymer nanotube mediated drug delivery to
glioblastoma multiforme spheroids
Glioblastoma Multiforme spheroids were prepared by seeding
U-87 cells in round-bottom ultra-low adherence 96-well plates
(COSTAR) at a concentration of 1000 cells per well, followed by
centrifugation at 300g for 1 minute. To allow spheroid forma-
tion, the cells were incubated at 37 C with 5% CO2 for 3 days.
Polymer nanotube dispersions were prepared as described
above for the 2D cell culture assays (unloaded and doxorubicin
loaded), but at double the nal concentration. They were added
to the spheroids, by removing half the cell medium and
replacing with medium containing the nanotubes. LightNanoscale Adv., 2020, 2, 4498–4509 | 4501
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View Article Onlinemicroscopy (Leica DMi1 inverted microscope) was used,
together with ImageJ soware, to determine the spheroid
diameters aer 0, 1, 3, 7 and 14 days of incubation. PrestoBlue
analysis was carried out aer 7 and 14 days using the method
outlined above. Experiments were performed with six replicates.
The feasibility of direct injection into spheroids was performed
using the doxorubicin-loaded nanotubes as described above, at
a nal concentration (once injected, including the medium
surrounding the spheroid) of 15 mg mL1. Glass capillaries were
pulled to an approximate outside diameter of 250 mm and
connected to the Hamilton syringe/polyethylene tubing as used
above. The medium was removed from the wells containing the
spheroids and a syringe driver (HLL Landgraf Laborsysteme,
Germany) was used to inject 0.25 mL of nanotube suspension or
free doxorubicin into the spheroid at a rate of 1 mL per minute.
This was performed under a stereo microscope (SE4, Leica)
using an eyepiece camera for imaging. Fluorescencemicroscopy
was performed to visualise the injected nanotubes (EVOS
M7000 Imaging System) and PrestoBlue analysis was performed
as above four days post-injection. Experiments were performed
with four replicates.Statistical analyses
Data was analysed using GraphPad Prism 6.07 (GraphPad)
soware. The cell viability of astrocytes was analysed via a two-
way ANOVA (treatment and dose) for each time point separately
with a Sidak post hoc comparisons test. The 2D cell viability
studies were analysed using a two-way ANOVA (treatment and
dose) for each time point separately with Tukey's post hoc
multiple comparisons test. Finally, the 3D cell viability studies
were analysed using a one-way ANOVA with Tukey's post-hoc
multiple comparisons test. Error bars represent the standard
deviation throughout, and an asterisk denotes statistical
signicance with P # 0.05. (Note – asterisks omitted from the
graphs of two-way ANOVA analyses for all concentrations below
120 mg mL1 for clarity).Results and discussion
Polymer nanotube synthesis and characterisation
Polymer nanotubes comprised of poly(ethylene glycol) were
successfully synthesised via a template synthesis procedure.
Template synthesized nanomaterials have been produced from
starting materials such as metals,36,37 nucleic acids,38 poly-
saccharides,39 proteins,40 and synthetic polymers like poly-
pyrrol41 and polystyrene42 Such a synthesis strategy gives tight
control over the diameter of the resulting nanotubes.43 A sche-
matic depiction of the synthesis process is shown in Fig. 1,
whereby photopolymerization was used to crosslink PEGDA
within the 200 nm diameter pores of an anodised aluminium
oxide (AAO) membrane. The resulting PEG based nanotubes
were released from the template via dissolution of the AAO
membrane in sodium hydroxide.
Scanning electron microscope (SEM) images show how
exible the nanotubes are, allowing them to deposit over and
around each other, with open pore ends on at least one end of4502 | Nanoscale Adv., 2020, 2, 4498–4509the nanotube (Fig. 1b and c). SEM analysis of the PEG nano-
tubes highlights the uniformity of their diameter which
contrasts the large variability exhibited by the multiwalled
carbon nanotubes (MWCNT) used as control nanotubes for
subsequent studies (ESI Fig. S1†). By adding a maleimide
functionalised uorescent dye to the monomer solution, uo-
rescently labelled nanotubes could be synthesized (Fig. 1d)
provided that the dye's absorption wavelength did not overlap
with the wavelength of UV light used for photopolymerization
(365 nm). This allowed detection of differently labelled nano-
tubes (Atto 463, 565 or 647) by uorescence microscopy
(Fig. S2†).Doxorubicin loading and release
We previously hypothesized that dissolution of the AAO
membrane, to release the nanotubes from the template, would
result in partial cleavage of the ethylene glycol chains present in
PEG based nanotubes, thus introducing carboxylic acid groups
on the nanotube surface.24 As doxorubicin contains a primary
amine group which can be protonated (pKa value of 8.2),44
reversible electrostatic interaction with the nanotubes was
envisaged. Fig. 2a shows a schematic depiction of the potential
mechanism of sodium hydroxide induced cleavage of PEG
chains together with the electrostatic interaction with doxoru-
bicin. We hypothesised that by varying the template dissolution
time (and hence exposure time to sodium hydroxide) we could
vary the degree of carboxylic acid functionalisation, which could
alter the doxorubicin uptake/release properties of the nano-
tubes. Raman spectroscopy analysis of nanotubes exposed to
sodium hydroxide for 10, 40 and 70 minutes (termed PEG-10,
PEG-40 and PEG-70 respectively) showed corresponding
increases in peak height at 1580 cm1, indicative of increasing
carboxylic acid functionalisation (Fig. S3†). Furthermore, incu-
bation of the three types of nanotubes with increasing
concentrations of doxorubicin did indeed highlight differences
in the loading capabilities of these nanotubes (Fig. 2b). As
predicted, PEG-70 showed the highest doxorubicin uptake,
removing all the doxorubicin from solutions up to a concentra-
tion of 48 mg mL1 (0.4 : 1 doxorubicin to nanotube weight
ratio). PEG-40, the standard nanotube used for all subsequent
studies, also showed highly efficient doxorubicin uptake,
removing all drug from a 12 mg mL1 concentration (0.1 : 1
doxorubicin to nanotube weight ratio). PEG-10 nanotubes were
unable to remove all the doxorubicin from the solutions tested
but still showed higher drug uptake than the multi-walled
carbon nanotube (MWCNT) controls.
To analyse the drug release prole from the nanotubes, all
four types were loaded with doxorubicin at a drug/nanotube
ratio of 0.8 : 1, i.e. above the saturation ratio determined
above. Aer washing off the excess drug, release was analysed
over a period of 21 days as shown in Fig. 2c and S4.†Most of the
drug was released over the rst seven days with a small amount
released over the following two weeks (3 mg (7% of loaded
drug)). This was true for the three types of PEG nanotubes, with
PEG-70 releasing more (as they were loaded with more doxo-
rubicin from the loading solution).This journal is © The Royal Society of Chemistry 2020
Fig. 2 Tuneable drug loading to the nanotubes. (a) Schematic depiction of the proposed mechanism of carboxylic acid group formation in the
nanotube structure via the sodium hydroxide mediated template dissolution step for either 10, 40 or 70 minutes. These negatively charged
groups subsequently drive the electrostatic loading of doxorubicin via its amino group. (b) PEG nanotubes removed from the template for either
10, 40 or 70minutes (termed PEG-10, PEG-40 or PEG-70 respectively) were loaded with varying concentrations of doxorubicin to determine the
maximum drug/nanotube loading ratio (saturation point) (n ¼ 4). MWCNT were used for a comparison. (c) Time course of doxorubicin release
from saturated nanotubes (n ¼ 4). (d) Fluorescent microscope images of nanotubes showing that empty nanotubes show no fluorescence at
480 nm excitation, whereas for doxorubicin loaded nanotubes the intrinsic fluorescence of doxorubicin overlaps with that of the Atto 647-
labelled nanotube (scale bars represent 25 mm).
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View Article OnlineUsing uorescently labelled (Atto-647) PEG nanotubes, the
doxorubicin uptake could also be visualized by laser scanning
confocal microscopy. Fig. 2d shows overlaid images of theThis journal is © The Royal Society of Chemistry 2020intrinsic uorescence of doxorubicin with the uorescently
labelled nanotubes, showing homogeneous doxorubicin uptake
along the nanotube length.Nanoscale Adv., 2020, 2, 4498–4509 | 4503
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View Article OnlinePEG nanotubes caused no reduction in cell viability
Carbon nanotubes have been investigated extensively for use in
drug delivery applications,27,45 but suffer the drawback ofFig. 3 Empty PEG nanotubes show significantly lower toxicity than MWC
assay, after incubation with PEG nanotubes or MWCNTs for three days (a)
significant difference to MWCNTs, (two way ANOVA with Sidak's multip
human astrocytes after three days of incubation with either PEG nanotu
Fig. 4 PEG nanotubes only show toxicity when loaded with doxorubicin.
empty nanotubes or doxorubicin loaded nanotubes (drug to nanotube w
PEG nanotubes only reduce C6 glioma viability when loaded with doxoru
doxorubicin loading (n¼ 4, error bars represent standard deviation, pos
difference to empty PEG nanotubes (two way ANOVAwith Tukey's multip
glioma cells after three days of culture showing impaired cell viability in
PEG nanotubes (nanotube concentration ¼ 15 mg mL1, scale bars repre
4504 | Nanoscale Adv., 2020, 2, 4498–4509inherent cytotoxicity due, in part, to their stiff 1-dimensional
structure.46 We have previously shown that template syn-
thesised polymer nanotubes are orders of magnitude less stiffNT. The viability of human astrocytes, as determined via the PrestoBlue
(n¼ 4, error bars represent standard deviation, * represents statistical
le comparison test (P # 0.05))). (b) Brightfield microscope images of
bes or MWCNTs (scale bars represent 100 mm).
C6 glioma cell viability analysis (PrestoBlue assay) after incubation with
eight ratio of 0.08 : 1) for one day (a) or three days (b) showing that the
bicin. MWCNTs show dose dependent toxicity which is augmented by
itive control¼ 4 mgmL1 doxorubicin, * represents statistical significant
le comparison test (P# 0.05))). (c) Brightfield microscope images of C6
the presence of MWCNTs (empty and loaded) and doxorubicin loaded
sent 100 mm, images of the positive control are in Fig. S7†).
This journal is © The Royal Society of Chemistry 2020
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View Article Onlinethan MWCNTs.24 We therefore hypothesised that the PEG
nanotubes, synthesised herein, would not be cytotoxic to in vitro
cell cultures. Astrocytes were chosen for initial cell viability
analysis because they are a predominant cell type of the brain.
We envisaged the development of a delivery system that did not
intrinsically cause toxicity but could deliver a chemotherapeutic
payload. Fig. 3 conrms that, at the highest concentration
analysed (120 mg mL1), the PEG nanotubes did not cause
a reduction in the viability of human astrocyte cells (as
measured by metabolic activity) in comparison to untreated
control cells when analysed aer 1 day (Fig. S5†) and 3 days in
culture (Fig. 3a). Brighteld images show that PEG nanotube
concentrations of 15 mgmL1 (Fig. 3b) and 60 mgmL1 (Fig. S5†)
result in a mass of nanotubes over the surface of the cells and
well. MWCNTs at these concentrations caused a reduction in
cell viability and can be observed as clumps associated with the
cells. The lack of cytotoxicity exhibited by the PEG nanotubes
reects our ndings via breast epithelial cells.24Drug loaded nanotubes kill glioblastoma cells in 2-
dimensional (2D) in vitro culture
Having established that PEG nanotubes caused no reduction in
astrocyte viability at concentrations up to 120 mg mL1, we next
wanted to assess the effect of doxorubicin loaded nanotubes onFig. 5 Drug loaded nanotubes reduce the viability of U-87 human gliobla
three days (b) of incubation with PEG or MWCNTs showing that both nano
(n¼ 4, error bars represent standard deviation, positive control¼ 4 mgm
PEG nanotubes (two way ANOVA with Tukey's multiple comparison tes
showing clear association of the MWCNTs with cells whereas PEG nanotu
mg mL1, scale bars represent 100 mm, images of the positive control ar
This journal is © The Royal Society of Chemistry 2020glioma and glioblastoma cell lines. We hypothesised that
unloaded (empty) nanotubes would not cause cytotoxicity
whereas doxorubicin loaded nanotubes could kill the brain
cancer cells, thus indicating that cell death is caused by the
released drug. Whilst the PrestoBlue assay, used herein,
measures cell metabolic activity, we have used it as an indicator
of cell health/viability by normalising to the untreated control
group. The viability of C6 glioma cells was analysed 1- and 3-
days post incubation with varying concentrations of MWCNT
and PEG nanotubes, either empty, or loaded with doxorubicin.
In a similar manner to astrocytes, unloaded MWCNTs caused
a reduction in C6 cell viability, whilst unloaded PEG nanotubes
did not (Fig. 4). Furthermore, both nanotube types caused
cytotoxicity, in a dose dependent manner, when loaded with
doxorubicin. In general, U-87 glioblastoma cells appeared to be
less affected by the drug loaded nanotubes, taking three days to
reduce the cell viability below 50% (Fig. 5). However, control
cells receiving 4 mg mL1 of free doxorubicin responded simi-
larly, indicating that U-87 cells are perhaps more chemo-
resistant than C6 cells. A similar study was carried out with
U251 malignant glioblastoma cells (Fig. S6†) which followed
a similar trend to the U-87 cells. These studies all showed that
the unloaded PEG nanotubes did not cause cell death (for all
cell types tested), indicating that a non-toxic delivery system can
be used to deliver a cytotoxic chemotherapeutic agent.stoma cells. Cell viability analysis (PrestoBlue assay) after one day (a) or
tube types reduce glioblastoma viability when loaded with doxorubicin
L1 doxorubicin, * represents statistical significant difference to empty
t (P # 0.05))). (c) Brightfield images taken after three days of culture
bes spread more evenly across the well (nanotube concentration ¼ 15
e in Fig. S7†).
Nanoscale Adv., 2020, 2, 4498–4509 | 4505
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View Article OnlineInjection of doxorubicin loaded PEG nanotubes into 3-
dimensional (3D) cultures of C6 glioma reduces their viability
A previous study using prostate cancer cell lines (LNCaP and
PC3 cells) highlighted that matching doses of doxorubicin gave
different cytotoxic outcomes depending on whether the cells
were cultured in 2D or in 3D (within a hydrogel).47 Both cell
types exhibited reduced chemosensitivity when cultured in a 3D
hydrogel platform.47 We therefore wanted to analyse whether
drug loaded nanotubes could still exert their cytotoxic effect on
cells cultured in a 3D microenvironment. We also wanted to
assess the feasibility of injecting the nanotubes, so
a Matrigel™-based 3D culture was used as a model to test focal
injection and tumour ablation in 3D culture.
Fig. 6 shows that doxorubicin loaded PEG nanotubes,
injected into the centre of the 3D culture model resulted in
a signicant reduction in C6 cell viability down to 23% three
days post-injection. This data corresponded well to the cell
viability of C6 cells cultured in 2D and incubated with the
same concentration of doxorubicin loaded nanotubes (7.5 mg
mL1) which had a mean viability of 21% aer three days
(Fig. 4b). Injection of unloaded nanotubes did not result in
a loss of glioma viability. In addition to the PrestoBlue cell
metabolic activity assay, live/dead analysis was performed by
confocal microscopy (Fig. S8†). This data shows that nano-
tubes are retained at the injection site and that the
doxorubicin-loaded nanotubes caused considerable cell death
in the 3D model.Fig. 6 Doxorubicin loaded PEG nanotubes reduced the viability of C6 g
glioma cells grown in Matrigel gel-drop culture either one day (a), or three
loaded PEG nanotubes (final concentration of 7.5 mg mL1). Cell viability w
mg mL1) served as a positive control (Pos Ctrl) (n ¼ 4, error bars represe
control (one way ANOVA with Tukey's multiple comparison test (P # 0.0
microscope images of the cells in 3D culture showing the nanotube inje
4506 | Nanoscale Adv., 2020, 2, 4498–4509Focal drug delivery, either directly to the tumour, or to the
surrounding tissue, represents a means of increasing the local
drug concentration in proximity to the tumour mass.48 As
described earlier, Gliadel wafers have been added to the resec-
tion cavity of GBM patients to release carmustine locally to
remaining non-resected cancer cells. However, aside from being
too big to inject to non-resectable tumours, the at shape of
Gliadel wafers, combined with their stiffness and brittleness,
make them poorly matched to the mechanical properties of the
brain. Furthermore, Gliadel wafers have been associated with
several adverse effects including convulsions, confusion, brain
oedema, infection, hemiparesis, aphasia, and visual eld
defects.49 These complications coupled with limited clinical
benets drives the rationale for developing alternative focal
drug delivery strategies.50 Here, we have demonstrated the
cytotoxic efficacy of PEG nanotubes, and the feasibility of
injecting them by means of a cannula set-up typically used for
intracerebral stereotactic injection into rodents.51Drug loaded nanotubes reduce glioblastoma multiforme
spheroid size and viability
The nal in vitro assay used to validate the cytotoxic efficiency of
the PEG nanotube drug delivery system utilized U-87 spheroid
culture. U8-7 cell spheroid culture more closely recapitulates
some aspects of tumour growth such as oxygen/nutrient gradi-
ents within the mass of cells,52 and has previously been used
during the assessment of doxorubicin loaded nanomedicines.53lioma cells cultured in a 3D environment. Cell viability analysis of C6
days (b) after injection of either empty PEG nanotubes, or doxorubicin
as normalised to untreated cells (control). Doxorubicin treated cells (4
nt  standard deviation, * represents statistical significant difference to
5))). (c) Depiction of injection into the Matrigel model with brightfield
ction site (indicated by black arrows) (scale bars represent 100 mm).
This journal is © The Royal Society of Chemistry 2020
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View Article OnlinePEG nanotube cytotoxicity was analysed using U-87 cell spher-
oids cultured over a longer time period (7 and 14 days). Fig. 7
shows that unloaded nanotubes did not cause a reduction in
spheroid viability or spheroid size in comparison to untreated
spheroids. However, doxorubicin loaded nanotubes resulted in
a reduction in viability to less than 52% for all nanotube
concentrations analysed. Doxorubicin loaded nanotubes at
a concentration of 15 mg mL1 caused a reduction in cell
viability to 45% and 35% aer 7 and 14 days respectively. This
corresponded with a 49% reduction in spheroid diameter
compared to the untreated controls aer 14 days. It is inter-
esting to note that in the 2D studies with the same cell type
(Fig. 5), a doxorubicin loaded PEG nanotube concentration of 15
mg mL1 appeared more cytotoxic, causing a large reduction in
viability to 18% already aer 3 days.
This discrepancy in cytotoxicity between 3D and 2D culture
indicates that U-87 glioblastoma cells cultured as a spheroid
may be more robust and less susceptible to anticancer thera-
peutics than their 2D culture counterpart. In the case ofFig. 7 Doxorubicin loaded nanotubes reduce the viability and size of h
formed from 1000 U-87 cells is reduced by doxorubicin and doxorubicin
days (a) and 14 days (b). Doxorubicin loaded PEG nanotubes (15 mgmL1) m
growth rate of the spheroid as determined by spheroid diameter (c), with
three days in culture (n ¼ 6, error bars represent  standard deviation, *
with Tukey's multiple comparison test (P # 0.05))). After 14 days of cultur
or spheroids cultured with doxorubicin loaded PEG nanotubes (15 mg m
This journal is © The Royal Society of Chemistry 2020doxorubicin this may be due to a hypoxic region forming at the
spheroid core52 reducing the cytotoxic action of the drug via
hypoxia inducible factor 1a related pathways.54,55 Our study was
conducted by adding the nanotubes to the medium
surrounding the spheroids which does not recapitulate the
process of intratumoural injection.
We then analysed the feasibility of injecting the doxorubicin
loaded nanotubes directly into the spheroid core which could
more accurately represent the focal drug delivery strategy
required for inoperable GBM tumours. This process was tech-
nically difficult to accomplish, although loaded nanotubes and
free drug could be successfully injected into the spheroids as
shown in Fig. S9.† Despite a syringe driver being used to control
the injection of nanotubes (0.25 mL) to a rate of 1 mL per minute,
not all the injected solution remained within the spheroid. We
conclude that this process would require further renement,
both in terms of the approach to injection, and the volumes/
rates injected, to yield a viable technique to mimic direct
tumoural injection. However, intraspheroid injection ofuman glioblastoma spheroids. The viability of glioblastoma spheroids
loaded nanotubes, as measured using the PrestoBlue assay after seven
ediated a reduction in viability which correlates with a reduction in the
4 mg of doxorubicin causing complete dissociation of the spheroid after
represents statistical significant difference to control (one way ANOVA
e, brightfield microscope images show untreated control spheroids (d)
L1) (e) (scale bars represent 500 mm).
Nanoscale Adv., 2020, 2, 4498–4509 | 4507
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View Article Onlinedoxorubicin loaded nanotubes could be visualised by uores-
cence microscopy, showing retention at the injection site, and
a corresponding reduction in viability (Fig. S9g and h†).
The use of doxorubicin in focal/local therapeutic strategies
offers potential for improving upon the currently poor prog-
nosis associated with glioblastoma multiforme. Not only has
doxorubicin been shown to be more potent against GBM cells in
culture than both carmustine56 and temozolomide,14 but in
addition, studies have indicated that a synergistic cytotoxic
mechanism exists between doxorubicin and temozolomide.57,58
Doxorubicin has also been used clinically for treatment of GBM
in conjunction with temozolomide via pegylated liposomal
doxorubicin,59 or the EnGeneIC delivery vehicle.60 These
delivery systems have been designed for systemic administra-
tion and the lack of improvement shown by these trials over
standard therapeutic strategies may in part be due to a low
concentration of the drug reaching the target site. In order to
maximise the potential for doxorubicin based strategies,
injectable local drug delivery systems need to be explored.61
Whilst the data herein does not show that doxorubicin-
loaded nanotubes are more effective than the free drug, these
in vitro models fail to recapitulate the complex nature of drug
dispersion, elimination and termination in vivo, where a termi-
nation half-life for doxorubicin of under 48 hours can be ex-
pected.62,63 Local drug delivery systemsmay therefore negate the
need for continuous or repeat administration to the tumour
site.
Conclusions
In summary, we have used a template-assisted synthesis
strategy to produce PEG-based nanotubes. The ability of the
nanotubes to be loaded with doxorubicin could be tuned simply
by varying the template dissolution time (and hence the degree
of carboxylic acid functionality). Doxorubicin was readily loaded
to the negatively charged PEG nanotubes via electrostatic
interaction with the positively charged (protonated) doxoru-
bicin. The loaded PEG nanotubes showed a slow release of
doxorubicin over 21 days with the majority released over the
rst week. In contrast to stiff MWCNT used as a reference, the
unloaded exible PEG nanotubes showed good biocompati-
bility across all cell types tested whilst the doxorubicin loaded
nanotubes reduced GBM cell viability (C6, U-87 and U-251) in
a dose dependent manner in 2D and 3D models. Focal admin-
istration of these injectable polymer nanotubes therefore holds
the potential to broaden the spectrum of anti-cancer drugs
available for GBM therapies.
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